Valuation: Revance Therapeutics, Inc.

Market Cap 319M 275M 259M 235M 443M 30.49B 450M 3.03B 1.19B 15.27B 1.2B 1.17B 50.75B P/E 2022
-3.77x
P/E 2023 -2.3x
Enterprise Value 543M 469M 441M 401M 754M 51.96B 767M 5.17B 2.02B 26.02B 2.04B 2B 86.47B EV / Sales 2022
12x
EV / Sales 2023 4.26x
Free-Float
91.93%
Yield 2022 *
-
Yield 2023 -
3 years 2.3
Extreme 2.3
19.01
5 years 2.3
Extreme 2.3
37.98
10 years 2.3
Extreme 2.3
37.98
Manager TitleAgeSince
Chief Executive Officer 55 2025-09-30
General Counsel - 2025-02-03
Director TitleAgeSince
Chairman - 2025-09-30
Date Insider Type Main position Quantity % Market Cap.
2/4/25 Tender

Chairman

51,506 0.0493%
2/4/25 Tender

Director

31,561 0.0302%
2/4/25 Tender

General Counsel

180,044 0.1725%
Change 5-day change 1-year change 3-year change Capi.($)
+0.27%-.--%-.--%-80.54% 383M
-0.31%+2.44%+38.43%+0.77% 80.23B
-1.02%-0.51%-2.54%+28.91% 50.64B
+1.55%-4.22%+10.31%+164.80% 46.87B
-1.39%+0.10%-50.39%-50.07% 46.34B
-0.39%+0.91%+51.39%-20.90% 31B
-0.52%+7.01%+125.98%-35.99% 25.28B
-0.30%-0.33%+38.24%+85.63% 24.36B
+2.13%-1.59%-6.04%+192.81% 20.81B
+1.54%-2.82%+60.85%+109.32% 16.08B
Average +0.16%+0.32%+26.62%+39.47% 34.2B
Weighted average by Cap. -0.09%+0.53%+22.41%+38.59%

Financials

2022 2023
Net sales 133M 114M 108M 97.85M 184M 12.68B 187M 1.26B 493M 6.35B 498M 487M 21.09B 234M 202M 190M 173M 325M 22.38B 330M 2.23B 870M 11.21B 879M 860M 37.24B
Net income -356M -308M -289M -263M -495M -34.08B -503M -3.39B -1.33B -17.07B -1.34B -1.31B -56.72B -324M -280M -263M -239M -450M -30.98B -457M -3.08B -1.2B -15.51B -1.22B -1.19B -51.55B
Net Debt 77.76M 67.16M 63.11M 57.4M 108M 7.44B 110M 739M 289M 3.72B 292M 286M 12.37B 225M 194M 182M 166M 312M 21.47B 317M 2.14B 835M 10.75B 843M 825M 35.73B
Logo Revance Therapeutics, Inc.
Revance Therapeutics Inc is a United States-based pharmaceutical preparation manufacturing company. The Company operates as a biotechnology company that develops, manufactures, and markets aesthetic and therapeutic products. It offers products and services, such as DAXXIFY (DaxibotulinumtoxinA-lanm) and resilient hyaluronic acid (RHA) collection, includes aesthetics and therapeutics.
Employees
597
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. RVNC Stock